Kumaraguru Raja
Stock Analyst at Brookline Capital
(n/a)
# 4,983
Out of 4,984 analysts
16
Total ratings
7.14%
Success rate
-49.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.24 | +1,139.67% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $0.58 | +2,670.56% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.61 | +459.01% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $2.58 | +210.08% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $11.96 | +736.12% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.02 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.35 | +43,127.67% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.10 | +383.87% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $5.51 | +281.13% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $66.64 | +35.05% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $3.42 | +8,964.33% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $5.58 | +602,050.54% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.24
Upside: +1,139.67%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $0.58
Upside: +2,670.56%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.61
Upside: +459.01%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $2.58
Upside: +210.08%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $11.96
Upside: +736.12%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.02
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.35
Upside: +43,127.67%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.10
Upside: +383.87%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $5.51
Upside: +281.13%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $66.64
Upside: +35.05%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $3.42
Upside: +8,964.33%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $5.58
Upside: +602,050.54%